| Literature DB >> 27416969 |
Dongzhi Yang1, Xiangnan Huang1, Chuanju Cui2, Yuchao Zhang3, Ya Li3, Xin Zang1, Ying He3, Hong Zheng3.
Abstract
No coding sequence variants of the ALOX5AP gene that lead to amino acid substitutions have been identified. A two-stage study design was used to explore the relationship between variants in the transcriptional regulatory region of ALOX5AP gene and ischemic stroke (IS) risk in Chinese populations. IS was determined using CT and/or MRI. First, 18 SNPs, located in the upstream promoter region of ALOX5AP gene, were genotyped in 200 IS patients and 200 controls. And one potential associated SNP (rs17222919) was identified (P = 0.005,OR = 0.623, 95% CI: 0.448~0.866). Next, another independent case-control cohort comprising 810 IS patients and 825 matched controls was recruited to investigate the role of rs17222919, rs9579646 polymorphisms and their haplotypes in IS risk. The G allele frequency of rs17222919 in the IS group was significantly lower than that in control group (P = 0.007, OR = 0.792, 95% CI: 0.669~0.937). T-A and G-A haplotypes were associated with IS (P = 0.001,OR = 1.282, 95% CI:1.100~1.495; P = 0.0001, OR = 0.712, 95% CI: 0.598~0.848; respectively). Our study providesevidence that rs17222919 is a potential genetic protective factor against IS. Furthermore, the T-A haplotype is a risk factor and the G-A haplotype is a protective factor against IS in Chinese population.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27416969 PMCID: PMC4945871 DOI: 10.1038/srep29513
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the two independent study populations.
| Initial study Population | Second study Population | |||||
|---|---|---|---|---|---|---|
| Cases(n = 200) | Controls(n = 200) | Cases(n = 810) | Controls(n = 825) | |||
| Sex (males/females) | 112/88 | 106/94 | 0.547 | 416/394 | 428/397 | 0.833 |
| Age (mean ± SD, years) | 57.2 ± 7.2 | 55.9 ± 7.0 | 0.090 | 57.7 ± 8.6 | 55.3 ± 7.2 | 0.243 |
| Total cholesterol (mmol/L) | 5.18 ± 1.09 | 4.54 ± 1.34 | 0.000 | 5.22 ± 1.17 | 4.62 ± 1.29 | 0.016 |
| Total triglyceride (mmol/L) | 1.89 ± 1.03 | 1.41 ± 1.01 | 0.000 | 1.94 ± 1.31 | 1.35 ± 1.13 | 0.017 |
| Hypertension, (n, %) | 80 (40.0) | 26 (13.0) | 0.000 | 469 (57.9) | 98 (11.9) | 0.000 |
| Diabetes, (n, %) | 32 (16.0) | 9 (4.5) | 0.000 | 134 (16.5) | 26 (3.2) | 0.000 |
| Smokers, (n, %) | 33 (16.5) | 20 (10.0) | 0.055 | 112 (13.8) | 64 (7.8) | 0.000 |
| Alcohol, (n, %) | 34 (17.0) | 28 (14.0) | 0.407 | 133 (16.4) | 118 (14.3) | 0.235 |
*P < 0.004 denotes statistical significance in the initial cohort.
*P < 0.025 denotes statistical significance in the second cohort.
The genotype and allelic distribution of 18 SNPs in the promoter region of ALOX5AP in IS and control subjects.
| SNP | Allele | Cases (n/%) | Controls (n/%) | ||
|---|---|---|---|---|---|
| 1785G>A | G | 400 | 400 | ||
| A | 0 | 0 | — | — | |
| 946A>G | A | 400 | 400 | ||
| G | 0 | 0 | — | — | |
| 581_582lnsA | D | 400 | 400 | ||
| I | 0 | 0 | — | — | |
| 519G>A | G | 400 | 400 | ||
| A | 0 | 0 | — | — | |
| 290G>A | G | 400 | 400 | ||
| A | 0 | 0 | — | — | |
| 190G>A | G | 400 | 400 | ||
| A | 0 | 0 | — | — | |
| rs34536374 | C | 331 (82.75) | 316 (79) | ||
| T | 69 (17.25) | 84 (21) | 0.178 | 0.784 (0.551–1.117) | |
| rs34344566 | G | 74 (18.5) | 88 (22) | ||
| A | 326 (81.5) | 312 (78) | 0.218 | 1.243 (0.879–1.756) | |
| rs9578194 | G | 322 (80.5) | 306 (76.5) | ||
| A | 78 (19.5) | 94 (23.5) | 0.169 | 0.789 (0.562–1.106) | |
| rs34352240 | T | 70 (17.5) | 88 (22) | ||
| C | 330 (82.5) | 312 (78) | 0.110 | 1.330 (0.937–1.887) | |
| rs34404999 | A | 62 (15.5) | 80 (20) | ||
| C | 338 (84.5) | 320 (80) | 0.096 | 1.363 (0.946–1.964) | |
| rs55950839 | T | 327 (81.75) | 311 (77.75) | ||
| A | 73 (18.25) | 89 (22.25) | 0.159 | 0.780 (0.552–1.103) | |
| rs55780307 | A | 340 (85) | 325 (81.25) | ||
| G | 60 (15) | 75 (18.75) | 0.157 | 0.765 (0.527–1.109) | |
| rs59227506 | T | 330 (82.5) | 319 (79.75) | ||
| C | 70 (17.5) | 81 (20.25) | 0.320 | 0.835 (0.586–1.191) | |
| rs12560847 | C | 180 (45) | 204 (51) | ||
| T | 220 (55) | 196 (49) | 0.089 | 1.272 (0.963–1.680) | |
| rs9578195 | G | 332 (83) | 315 (78.75) | ||
| A | 68 (17) | 85 (21.25) | 0.126 | 0.759 (0.533–1.082) | |
| rs61947373 | G | 231 (57.75) | 253 (63.25) | ||
| A | 169 (42.25) | 147 (36.75) | 0.112 | 1.259 (0.948–1.673) | |
| rs17222919 | T | 322 (80.5) | 288 (72) | ||
| G | 78 (19.5) | 112 (28) |
P value and OR (95% CI) were adjusted for confounding factors such as age, gender, hypertension, diabetes, smoking, drinking, TC and TG. Adjusted P value (P < 0.004) indicates statistical significance.
Figure 1The results of linkage disequilibrium tests for the twelve analyzed SNPs (The order is rs34536374, rs34344566, rs34352240, rs9578194, rs55950839, rs55780307, rs59227506, rs34404999, rs12560847, rs9578195, rs61947373 and rs17222919 from left to right).
Comparison of haplotype frequencies of eight SNPs excluding rs17222919 between IS and controls.
| Haplotype | IS group | Control group | χ2 | ||
|---|---|---|---|---|---|
| (2n = 400,%) | (2n = 400,%) | ||||
| C A C A T A T G | 4.00 (0.010) | 7.00 (0.018) | — | — | |
| C A C A T G T G | 0.00 (0.000) | 1.00 (0.003) | — | — | |
| C A C G A A C G | 2.00 (0.005) | 6.09 (0.015) | — | — | |
| C A C G A A T G | 0.00 (0.000) | 6.02 (0.015) | — | — | |
| C A C G T A C G | 4.06 (0.010) | 2.03 (0.005) | — | — | |
| C A C G T A T A | 4.00 (0.010) | 3.00 (0.008) | — | — | |
| C A C G T A T G* | 297.94 (0.745) | 275.81 (0.690) | 4.347 | 0.037 | 1.540 [1.024~2.314] |
| C A C G T G T G | 0.00 (0.000) | 3.05 (0.008) | — | — | |
| C A T G T A T G | 4.00 (0.010) | 6.00 (0.015) | — | — | |
| C G C A T A T G | 4.00 (0.010) | 2.00 (0.005) | — | — | |
| C G C G T A T G | 4.00 (0.010) | 4.00 (0.010) | — | — | |
| T A C A T A T G | 2.00 (0.005) | 2.00 (0.005) | — | — | |
| T G T A A A C A | 9.98 (0.025) | 4.94 (0.012) | — | — | |
| T G T A A A T A | 2.02 (0.005) | 2.02 (0.005) | — | — | |
| T G T A A G C A* | 46.96 (0.117) | 66.92 (0.167) | 4.347 | 0.037 | 0.650 [0.432~0.976] |
| T G T A A G T A | 4.04 (0.010) | 3.01 (0.008) | — | — | |
| T G T A T A T A | 0.00 (0.000) | 4.09 (0.010) | — | — | |
| T G T A T G C A | 1.00 (0.003) | 1.02 (0.003) | — | — | |
| C A C G A G C G | 6.00 (0.015) | 0.00 (0.000) | — | — | |
| C G C A A G T G | 1.00 (0.003) | 0.00 (0.000) | — | — | |
| T A T A T A T G | 2.00 (0.005) | 0.00 (0.000) | — | — | |
| T G C A A G T G | 1.00 (0.003) | 0.00 (0.000) | — | — |
Adjusted P value (P < 0.004) indicates statistical significance.
Genotype and allelic distribution of rs l7222919 and rs9579646 in IS and control subjects.
| Genotype | IS subjects (n,%) | Control subjects (n,%) | ||
|---|---|---|---|---|
| rs l7222919 | ||||
| TT | 525 (64.8) | 486 (58.9) | 1.000 | |
| TG | 258 (31.9) | 296 (35.9) | 0.043 | 0.807 (0.656~0.993) |
| GG | 27 (3.3) | 43 (5.2) | 0.031 | 0.581 (0.354~0.955) |
| allele | ||||
| T | 1308 (80.7) | 1268 (76.8) | 1.000 | |
| G | 312 (19.3) | 382 (23.2) | 0.007 | 0.792 (0.669~0.937) |
| rs 9579646 | ||||
| AA | 185 (22.8) | 179 (21.7) | 1.000 | |
| AG | 391 (48.3) | 422 (51.2) | 0.386 | 0.896 (0.700~1.148) |
| GG | 234 (28.9) | 224 (27.1) | 0.939 | 1.011 (0.768~1.331) |
| A | 761 (47.0) | 780 (47.3) | 1.000 | |
| G | 859 (53.0) | 870 (52.7) | 0.865 | 1.012 (0.882~1.161) |
The P value and OR (95% CI) were adjusted for confounding factors such as age, gender, hypertension, diabetes, smoking, drinking, TC and TG. *express the adjusted P value for significance P < 0.025.
Detailed association of rsl7222919 with IS risk in IS and control groups under different genetic models.
| Model | Case (n, %) | Control (n, %) | χ2 | ||
|---|---|---|---|---|---|
| Dominant | |||||
| TG + GG | 285 (35.2) | 339 (41.1) | 6.040 | 0.014 | 0.778 (0.637–0.951) |
| Recessive | |||||
| GG | 27 (3.3) | 43 (5.2) | 3.520 | 0.061 | 0.627 (0.384–1.025) |
| Additive | |||||
| TT | 525 (64.8) | 486 (58.9) | |||
| TG | 258 (31.9) | 296 (35.9) | 4.110 | 0.043 | 0.807 (0.656 –0.993) |
| GG | 27 (3.3) | 43 (5.2) | 4.674 | 0.031 | 0.581 (0.354–0.955) |
*express the P value for significance P < 0.025.
Haplotpype analysis of rsl7222919 and rs9579646 in IS and control groups.
| Haplotype | Case (2n = 1620,%) | Control (2n = 1650,%) | ||
|---|---|---|---|---|
| G-G | 41 (2.5) | 19 (1.2) | — | — |
| T-G | 818 (50.5) | 851 (51.5) | 0.536 | 0.958 (0.835–1.098) |
| G-A | 271 (16.7) | 363 (22) | 0.0001 | 0.712 (0.598–0.848) |
| T-A | 490 (30.3) | 417 (25.3) | 0.001 | 1.282 (1.100–1.495) |
Note. Haplotypes with frequency <0.03 not considered in this analysis. *Significant differences between control and case groups (P < 0.025).